Replies to post #106692 on Biotech Values

[ghmm]

Appreciate the info and thanks also pollyvonwog for getting the info from the company. This blurb gives a little more info on genisi's comments:

http://www.smart-biggar.ca/Assets/RxIPUpdate_Jul05.pdf

Novopharm received its NOC for a generic version of LOVENOX ("Novo-enoxaparin") on February 28,
2005, and Aventis has commenced an action for patent infringement against Novopharm. Judge
dismisses Aventis' motion for an interlocutory or interim injunction to restrain Novopharm from, among
other things, selling Novo-enoxaparin pending trial. Judge finds that Aventis failed to demonstrate that
it will suffer irreparable harm if an injunction is not issued. Aventis has appealed.

I think Teva will eventually launch but having it not developed in house would lead me to think it is more probable to be later then sooner.

Whomever contacts Teva next how about just saying I am a Momenta shareholder can you tell me when you think you will get approval to launch... then we can analyze how believable their reply is ;-).